Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Echinomycin SCHEMBL18506201 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL13464701 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL29529894 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL63091 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL29420869 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL30725384 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL18477111 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL20323949 | 0.96 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL12556535 | 0.95 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL29378829 | 0.95 | RIPK1 (0.32) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105992634-A | Selective modification of polymer subunits to improve nanopore-based assays | 华盛顿大学商业中心 | 2016-10-05 | — | — | CN | claimed |
| CN-102755628-B | Antifungal pharmaceutical composition | CHINESE ACAD INST MICROBIOLOGY | 2013-10-23 | — | — | CN | claimed |
| CN-102391968-B | Streptomyces and its application in echinomycin production | CHINESE ACAD INST MICROBIOLOGY | 2012-12-19 | — | — | CN | claimed |
| CN-102791260-A | Use of hypoxia inducible factor inhibitors | SUNVITA THERAPEUTICS LLC | 2012-11-21 | — | — | CN | claimed |
| CN-102755628-A | Antifungal pharmaceutical composition | CHINESE ACAD INST MICROBIOLOGY | 2012-10-31 | — | — | CN | claimed |
| CN-102391968-A | Streptomyces and its application in echinomycin production | CHINESE ACAD INST MICROBIOLOGY | 2012-03-28 | — | — | CN | claimed |
| CN-101795688-A | Use of 4- (pyrrolidin-1-yl) quinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LTD | 2010-08-04 | — | — | CN | claimed |
| CN-101351203-A | Application of pyrroloquinoline compound in killing clinically latent microorganisms | HELPERBY THERAPEUTICS LTD (GB) | 2009-01-21 | — | — | CN | claimed |
| CN-101312748-A | Antibody-drug conjugates and methods of use | MEDAREX INC (US) | 2008-11-26 | — | — | CN | claimed |
| CN-1997402-A | Cytotoxic compounds and conjugates | MEDAREX INC (US) | 2007-07-11 | — | — | CN | claimed |
| CN-1684642-A | Drug release from an antithrombotic multilayer coated stent | MEDIPLEX CORP (KR) | 2005-10-19 | — | — | CN | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-3137603-B1 | A NOVEL AFFINITY MATRIX AND DEVICES FOR ISOLATION AND PURIFICATION OF RNA AND DNA FOR POINT OF CARE MOLECULAR DEVICES | ACCUDX CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| WO-2024002385-A1 | ECHINOMYCIN ANTIBIOTIC MICELLE, PREPARATION METHOD THEREFOR, AND USE | 成都华昊中天药业有限公司 | 2024-01-04 | — | — | WO | disclosed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | disclosed |
| CN-1238700-A | Improvements in or relating to diagnostic and/or therapeutic agents | NYCOMED IMAGING AS (NO) | 1999-12-15 | — | — | CN | disclosed |
| CN-1234742-A | Improvements in or relating to diagnostic and/or therapeutic agents | NYCOMED IMAGING AS (NO) | 1999-11-10 | — | — | CN | disclosed |
| CN-1142828-A | Tetrahydrofuran antifungals | SCHERING CORP (US) | 1997-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | RIPK1 807/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | RIPK1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.